Pulmatrix (NASDAQ:PULM) Now covered by analysts at StockNews.com

StockNews.com has begun coverage of the stock Pulmatrix (NASDAQ:PULM – Free Report) in a research report published on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix trading down 1.4%

Shares of PULM stock opened at $2.05 on Thursday. The firm has a 50-day moving average of $2.08 and a 200-day moving average of $1.94. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $2.75. The firm has a market cap of $7.48 million, a P/E ratio of -0.85 and a beta of 0.99.

About Pulmatrix

(Get a free report)

Pulmatrix, Inc, a clinical-stage biotechnology company, is focused on developing novel inhaled therapeutics for the prevention and treatment of respiratory diseases and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform that enables the delivery of small or large molecule drugs to the lungs via inhalation for local or systemic applications.

Recommended articles

Get news and reviews for Pulmatrix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pulmatrix and related companies with MarketBeat.com’s FREE daily email newsletter.